0001193125-24-006011.txt : 20240213 0001193125-24-006011.hdr.sgml : 20240213 20240110170055 ACCESSION NUMBER: 0001193125-24-006011 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Coya Therapeutics, Inc. CENTRAL INDEX KEY: 0001835022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 12645 MEMORIAL DR., SUITE F1 #305 CITY: HOUSTON STATE: TX ZIP: 77024 BUSINESS PHONE: 650.739.3939 MAIL ADDRESS: STREET 1: 12645 MEMORIAL DR., SUITE F1 #305 CITY: HOUSTON STATE: TX ZIP: 77024 CORRESP 1 filename1.htm CORRESP

January 10, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:

Coya Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-276374)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on January 12, 2024, or as soon as practicable thereafter.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

 

Very truly yours,
COYA THERAPEUTICS, INC.
By:   /s/ Howard Berman
Name:   Howard Berman
Title:  

Chief Executive Officer

(Principal Executive Officer)